Abstract
Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
Keywords: Glioblastoma, glioblastoma stem cells, molecular target, therapy.
Recent Patents on Anti-Cancer Drug Discovery
Title:Therapeutic Strategies Targeting Glioblastoma Stem Cells
Volume: 8 Issue: 3
Author(s): Estefania Carrasco-Garcia, Nicolas Sampron, Paula Aldaz, Olatz Arrizabalaga, Jorge Villanua, Cristina Barrena, Irune Ruiz, Mariano Arrazola, Charles Lawrie and Ander Matheu
Affiliation:
Keywords: Glioblastoma, glioblastoma stem cells, molecular target, therapy.
Abstract: Glioblastoma is the most common, aggressive and lethal brain tumor in adults. However, current therapeutic protocols have low success rates and average overall survival is less than 15 months. The resistance to therapy is largely a result of the remarkable cellular and phenotypical heterogeneity that characterizes this type of tumor. The discovery of a subpopulation of cells exhibiting stem cell properties within the tumor bulk has profound implications for therapy as increasing evidence indicates that these cells, glioblastoma stem cells (GSCs), are responsible for the origin, maintenance and recurrence of the glioblastomas. These findings highlight the need to characterize GSCs in order to find novel treatments directly targeted specifically against them. In this review, we summarize the current knowledge regarding this issue, including some recent and relevant patents.
Export Options
About this article
Cite this article as:
Carrasco-Garcia Estefania, Sampron Nicolas, Aldaz Paula, Arrizabalaga Olatz, Villanua Jorge, Barrena Cristina, Ruiz Irune, Arrazola Mariano, Lawrie Charles and Matheu Ander, Therapeutic Strategies Targeting Glioblastoma Stem Cells, Recent Patents on Anti-Cancer Drug Discovery 2013; 8 (3) . https://dx.doi.org/10.2174/15748928113089990002
DOI https://dx.doi.org/10.2174/15748928113089990002 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Harnessing the Capacity of Cell-Penetrating Peptides for Drug Delivery to the Central Nervous System
Current Pharmaceutical Biotechnology Recent Advances of Radionuclide-Based Molecular Imaging of Atherosclerosis
Current Pharmaceutical Design microRNA as Biomarkers and Regulator of Cardiovascular Development and Disease
Current Pharmaceutical Design AKT and cytosolic phospholipase A<sub>2</sub>α form a positive loop in prostate cancer cells
Current Cancer Drug Targets Molecular Targeted Therapy of Hepatocellular Carcinoma – Results of the First Clinical Studies
Current Cancer Drug Targets Chemistry and Biology of Curacin A
Current Pharmaceutical Design Delivering the "Blueprints" or "DNA Repairing Kits" Instead of Drugs in the Treatment of Congenital Hemoglobinopathies
Current Organic Chemistry Meet Our Editorial Board Member
Recent Patents on Anti-Cancer Drug Discovery Recent Developments Towards the Synthesis of Varitriol: An Antitumour Agent from Marine Derived Fungus Emericella Variecolor
Current Organic Synthesis Insulin Decreases Therapeutic Efficacy in Colon Cancer Cell Line HT29 Via the Activation of the PI3K/Akt Pathway
Current Drug Discovery Technologies Biological Activities, Mechanisms of Action and Biomedical Prospect of the Antitumor Ether Phospholipid ET-18-OCH3 (Edelfosine), A Proapoptotic Agent in Tumor Cells
Current Drug Metabolism Low Content of Protein S29 in Ribosomes of Human Lung Cancer Cell Line A549: Detected by Twodimensional Electrophoresis
Protein & Peptide Letters Genomic Instability and Cancer
Current Molecular Medicine Cytotoxic Stilbenes and Derivatives as Promising Antimitotic Leads for Cancer Therapy
Current Pharmaceutical Design Editorial (Hot Topic: Cytochrome P450s: New Insights and Relevance to Medicinal Chemistry and Drug Discovery)
Current Topics in Medicinal Chemistry Living Life to the Fullest: Early Integration of Palliative Care into the Lives of Children with Chronic Complex Conditions
Current Pediatric Reviews Nature: A Substantial Source of Auspicious Substances with Acetylcholinesterase Inhibitory Action
Current Neuropharmacology Interaction of Wharton's Jelly Derived Fetal Mesenchymal Cells with Tumor Cells
Current Stem Cell Research & Therapy Recent Patents of Gene Mutation Relative to JAK/STAT Pathway and Their Implication in Myeloproliferative Diseases
Recent Patents on DNA & Gene Sequences A Review of Recent Patents on the Protozoan Parasite HSP90 as a Drug Target
Recent Patents on Biotechnology